Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

PHARMADAN A/S

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   4.2% 3.8% 7.4% 14.0% 11.7% 11.3% 14.5% 14.5%   Credit score (0-100)   51 53 34 16 19 20 14 15   Credit rating   BBB BBB BB BB BB BB BB BB   Credit limit (kDKK)   0.0 0.0 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   973 956 -1,761 -2,844 -3,128 -4,923 0.0 0.0   EBITDA   -1,700 -680 -1,761 -2,844 -3,128 -4,923 0.0 0.0   EBIT   -2,057 -1,028 -2,079 -3,158 -3,440 -5,215 0.0 0.0   Pre-tax profit (PTP)   -2,110.6 -1,050.8 -2,074.6 -3,219.6 -3,529.3 -5,404.9 0.0 0.0   Net earnings   -1,646.3 -799.8 -1,618.2 -2,511.3 -2,752.9 -4,167.7 0.0 0.0   Pre-tax profit without non-rec. items   -2,111 -1,051 -2,075 -3,220 -3,529 -5,405 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Tangible assets total   1,970 1,622 1,304 990 785 494 0.0 0.0   Shareholders equity total   3,435 2,635 1,017 -1,494 -4,247 -8,415 -9,015 -9,015   Interest-bearing liabilities   852 531 2,096 4,332 6,692 12,669 9,015 9,015   Balance sheet total (assets)   5,486 3,979 3,323 3,113 2,683 4,518 0.0 0.0   Net Debt   846 526 2,089 4,247 6,692 12,668 9,015 9,015     See the entire balance sheet 1000.0 Volume  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   973 956 -1,761 -2,844 -3,128 -4,923 0.0 0.0   Gross profit growth   66.3% -1.8% 0.0% -61.5% -10.0% -57.4% 0.0% 0.0%   Employees   4 3 0 0 0 0 0 0   Employee growth %   -20.0% -25.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   5,486 3,979 3,323 3,113 2,683 4,518 0 0   Balance sheet change%   -11.5% -27.5% -16.5% -6.3% -13.8% 68.4% -100.0% 0.0%   Added value   -2,057.4 -1,027.8 -2,079.3 -3,158.2 -3,440.0 -5,214.6 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -714 -697 -636 -628 -516 -583 -494 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -2.0 -3.0 -4.0 -5.0 -5.0 -5.0 0.0 0.0   1000.0 Profitability  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   -211.4% -107.5% 118.1% 111.0% 110.0% 105.9% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -32.6% -21.6% -56.8% -79.7% -59.3% -52.5% 0.0% 0.0%   ROI %   -37.2% -25.0% -62.9% -84.8% -62.0% -53.9% 0.0% 0.0%   ROE %   -34.2% -26.4% -88.6% -121.6% -95.0% -115.8% 0.0% 0.0%   1000.0 Solidity  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Equity ratio %   62.6% 66.2% 30.6% -32.4% -61.3% -65.1% -100.0% -100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -49.7% -77.3% -118.6% -149.3% -213.9% -257.3% 0.0% 0.0%   Gearing %   24.8% 20.2% 206.1% -289.9% -157.6% -150.6% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   1.5% 3.9% 0.2% 1.9% 2.0% 2.0% 0.0% 0.0%   1000.0 Liquidity  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Quick Ratio   1.1 1.1 0.3 0.3 0.2 0.2 0.0 0.0   Current Ratio   2.2 2.3 0.9 0.5 0.3 0.3 0.0 0.0   Cash and cash equivalent   6.8 5.6 6.4 84.9 0.5 0.4 0.0 0.0   1000.0 Capital use efficiency  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   1,904.6 1,324.3 -286.8 -2,484.0 -5,032.2 -8,908.4 -4,507.4 -4,507.4   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2017 2018/6 2018 2019/6 2019 2020/6 2020 2021/6 2021 2022/6 2022 2023/6 2023e N/A 2024e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   -514 -343 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   -425 -227 0 0 0 0 0 0   EBIT / employee   -514 -343 0 0 0 0 0 0   Net earnings / employee   -412 -267 0 0 0 0 0 0